Clinical Trial Update: Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene [Phase 1, Phase 2]

View source ↗

Summary

The document reports the completion of a Phase 1/2 clinical trial evaluating QR-110 for Leber congenital amaurosis due to CEP290 mutation, with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Congenital Amaurosis

Drugs mentioned

• QR-110

Snippet

Sponsor: Laboratoires Thea | Conditions: Leber's Congenital Amaurosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-27